Nasus Pharma is trading at $3.75, up +10.14% on September 14, 2026, after the FDA cleared its IND application for NS002, an investigational intranasal epinephrine powder for anaphylaxis.
- The company plans to begin the pivotal study during the fourth quarter of 2026 and expects topline results in the first quarter of 2027.
- The move is company-specific, despite broader market weakness and healthcare-sector strength.